Our results suggest that the pharmacologic targeting of the Cobll1/PACSIN2/SH3BP1 axis can be a novel approach to overcome TKI resistance and disease progression in CML. Here, PACSIN2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.